ACRX
- AcelRx Pharmaceuticals, Inc.
()
Overview
Company Summary
AcelRx Pharmaceuticals, Inc. is a pharmaceutical company that focuses on the development and commercialization of innovative therapies for acute pain management. Their primary goal is to provide alternative treatment options to patients who require rapid and effective pain relief in a medically supervised setting.
AcelRx specializes in developing therapies based on their proprietary sublingual sufentanil technology, which is a potent opioid analgesic. This technology allows for the rapid and efficient delivery of pain medication through the thin lining under the tongue.
The company's flagship product is Dsuvia� (sufentanil sublingual tablet), which is designed for the treatment of severe acute pain in medically supervised settings. Dsuvia offers a non-invasive, easy-to-administer option for patients who cannot tolerate oral medications or need immediate pain relief.
AcelRx also has other product candidates in its pipeline, including Zalviso�, a sufentanil sublingual tablet system for the management of moderate-to-severe acute pain and ARX-04, a sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain in an ambulatory setting.
Overall, AcelRx Pharmaceuticals focuses on developing and commercializing innovative pain management therapies, with a specific focus on providing rapid and effective relief to patients experiencing acute pain episodes.